Antibacterial Activity of LCB10-0200 against <i>Klebsiella pneumoniae</i>
<i>Klebsiella pneumoniae</i> is one of the important clinical organisms that causes various infectious diseases, including urinary tract infections, necrotizing pneumonia, and surgical wound infections. The increase in the incidence of multidrug-resistance <i>K. pneumoniae</i>...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/10/10/1185 |
| _version_ | 1797515485066035200 |
|---|---|
| author | Sang-Hun Oh Young-Rok Kim Hee-Soo Park Kyu-Man Oh Young-Lag Cho Jin-Hwan Kwak |
| author_facet | Sang-Hun Oh Young-Rok Kim Hee-Soo Park Kyu-Man Oh Young-Lag Cho Jin-Hwan Kwak |
| author_sort | Sang-Hun Oh |
| collection | DOAJ |
| description | <i>Klebsiella pneumoniae</i> is one of the important clinical organisms that causes various infectious diseases, including urinary tract infections, necrotizing pneumonia, and surgical wound infections. The increase in the incidence of multidrug-resistance <i>K. pneumoniae</i> is a major problem in public healthcare. Therefore, a novel antibacterial agent is needed to treat this pathogen. Here, we studied the in vitro and in vivo activities of a novel antibiotic LCB10-0200, a siderophore-conjugated cephalosporin, against clinical isolates of <i>K. pneumoniae</i>. In vitro susceptibility study found that LCB10-0200 showed potent antibacterial activity against <i>K. pneumoniae</i>, including the beta-lactamase producing strains. The in vivo efficacy of LCB10-0200 was examined in three different mouse infection models, including systemic, thigh, and urinary tract infections. LCB10-0200 showed more potent in vivo activity than ceftazidime in the three in vivo models against the drug-susceptible and drug-resistant <i>K. pneumoniae</i> strains. Taken together, these results show that LCB10-0200 is a potential antibacterial agent to treat infection caused by <i>K. pneumoniae</i>. |
| first_indexed | 2024-03-10T06:46:06Z |
| format | Article |
| id | doaj.art-3f4c7fc378ab4cfd96a0db84cb9bf042 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-10T06:46:06Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-3f4c7fc378ab4cfd96a0db84cb9bf0422023-11-22T17:13:24ZengMDPI AGAntibiotics2079-63822021-09-011010118510.3390/antibiotics10101185Antibacterial Activity of LCB10-0200 against <i>Klebsiella pneumoniae</i>Sang-Hun Oh0Young-Rok Kim1Hee-Soo Park2Kyu-Man Oh3Young-Lag Cho4Jin-Hwan Kwak5School of Life Science, Handong Global University, Pohang 37554, KoreaSchool of Life Science, Handong Global University, Pohang 37554, KoreaSchool of Food Science and Biotechnology, Kyungpook National University, Daegu 41566, KoreaLegoChem Bioscience Inc., Daejeon 34302, KoreaLegoChem Bioscience Inc., Daejeon 34302, KoreaSchool of Life Science, Handong Global University, Pohang 37554, Korea<i>Klebsiella pneumoniae</i> is one of the important clinical organisms that causes various infectious diseases, including urinary tract infections, necrotizing pneumonia, and surgical wound infections. The increase in the incidence of multidrug-resistance <i>K. pneumoniae</i> is a major problem in public healthcare. Therefore, a novel antibacterial agent is needed to treat this pathogen. Here, we studied the in vitro and in vivo activities of a novel antibiotic LCB10-0200, a siderophore-conjugated cephalosporin, against clinical isolates of <i>K. pneumoniae</i>. In vitro susceptibility study found that LCB10-0200 showed potent antibacterial activity against <i>K. pneumoniae</i>, including the beta-lactamase producing strains. The in vivo efficacy of LCB10-0200 was examined in three different mouse infection models, including systemic, thigh, and urinary tract infections. LCB10-0200 showed more potent in vivo activity than ceftazidime in the three in vivo models against the drug-susceptible and drug-resistant <i>K. pneumoniae</i> strains. Taken together, these results show that LCB10-0200 is a potential antibacterial agent to treat infection caused by <i>K. pneumoniae</i>.https://www.mdpi.com/2079-6382/10/10/1185LCB10-0200<i>Klebsiella pneumoniae</i>siderophorecephalosporin |
| spellingShingle | Sang-Hun Oh Young-Rok Kim Hee-Soo Park Kyu-Man Oh Young-Lag Cho Jin-Hwan Kwak Antibacterial Activity of LCB10-0200 against <i>Klebsiella pneumoniae</i> Antibiotics LCB10-0200 <i>Klebsiella pneumoniae</i> siderophore cephalosporin |
| title | Antibacterial Activity of LCB10-0200 against <i>Klebsiella pneumoniae</i> |
| title_full | Antibacterial Activity of LCB10-0200 against <i>Klebsiella pneumoniae</i> |
| title_fullStr | Antibacterial Activity of LCB10-0200 against <i>Klebsiella pneumoniae</i> |
| title_full_unstemmed | Antibacterial Activity of LCB10-0200 against <i>Klebsiella pneumoniae</i> |
| title_short | Antibacterial Activity of LCB10-0200 against <i>Klebsiella pneumoniae</i> |
| title_sort | antibacterial activity of lcb10 0200 against i klebsiella pneumoniae i |
| topic | LCB10-0200 <i>Klebsiella pneumoniae</i> siderophore cephalosporin |
| url | https://www.mdpi.com/2079-6382/10/10/1185 |
| work_keys_str_mv | AT sanghunoh antibacterialactivityoflcb100200againstiklebsiellapneumoniaei AT youngrokkim antibacterialactivityoflcb100200againstiklebsiellapneumoniaei AT heesoopark antibacterialactivityoflcb100200againstiklebsiellapneumoniaei AT kyumanoh antibacterialactivityoflcb100200againstiklebsiellapneumoniaei AT younglagcho antibacterialactivityoflcb100200againstiklebsiellapneumoniaei AT jinhwankwak antibacterialactivityoflcb100200againstiklebsiellapneumoniaei |